Alexion Pharmaceuticals (ALXN) : Money flow in the Alexion Pharmaceuticals (ALXN) stock was negative (4.53 million) on Tuesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $12.07 million, compared to $16.61 million on downticks. The total uptick to downtick ratio was 0.73, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($2.76 million), indicating selling on the strength. The transaction value during uptick in block trades was $1.93 million. Downtick transaction value in block trades amounted to $4.69 million, indicating persistent selling. The uptick to downtick ratio was 0.41. Alexion Pharmaceuticals (ALXN) traded $0.08 higher at $128.07 gaining 0.06% over the previous days close.
Also, Equity Analysts at the Barclays maintains the rating on Alexion Pharmaceuticals (NASDAQ:ALXN). The brokerage firm has issued a Equal-weight rating on the shares. The Analysts at the ratings agency lowers the price target from $165 per share to $150 per share. The rating by the firm was issued on July 29, 2016.
Alexion Pharmaceuticals, Inc. has lost 6.69% in the last five trading days and dropped 3.96% in the last 4 weeks. Alexion Pharmaceuticals, Inc. has dropped 16.03% during the last 3-month period . Year-to-Date the stock performance stands at -32.78%.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $127.77 and $127.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $129.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $128.22, notching a gain of 0.18% for the day. The total traded volume was 823,792 . The stock had closed at $127.99 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Wagner Heidi L, officer (SVP, Global Government Affairs) of Alexion Pharmaceuticals Inc, had unloaded 222 shares at an average price of $137.14 in a transaction dated on August 8, 2016. The total value of the transaction was worth $30,445.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.